Vera Therapeutics appoints Sean P. Grant as CFO; Jonathan Wolter resigns

Vera Therapeutics, Inc.

Sean P. Grant named CFO effective July 12, 2021; annual base salary $400,000.
Grant receives option to purchase 180,000 shares vesting over 4 years.
Previous CFO Jonathan Wolter resigned effective July 14, 2021; no disagreement cited.
Grant previously VP of Corporate Strategy at CareDx and VP in Citigroup Healthcare Investment Banking.
Employment letter includes severance of 9 months salary (12 months on change in control).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sean P. Grant

Chief Financial Officer

VERA · Vera Therapeutics, Inc.

Effective: 2021-07-12
Filed: July 14, 2021, 7:59 PM ET

On July 14, 2021, Vera Therapeutics, Inc. (the “Company”) announced the appointment of Sean P. Grant as the Company’s Chief Financial Officer, effective July 12, 2021 (the “Start Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sean P. Grant was appointed as Chief Financial Officer at Vera Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On July 14, 2021, Vera Therapeutics, Inc. (the “Company”) announced the appointment of Sean P. Grant as the Company’s Chief Financial Officer, effective July 12, 2021 (the “Start Date”).

View on SEC.gov

Vera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-215234

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.